Site Editor

Al B. Benson III, MD, FACP, FASCO

Advertisement
Advertisement

FDA Brief: Fast Track Designation Granted to STAT3 Inhibitor in Liver Cancer

By: JNCCN 360 Staff
Posted: Friday, October 21, 2022

On October 19, 2022, the biopharmaceutical company Tvardi Therapeutics, Inc. announced that its product TTI-101 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma. TTI-101 is an orally delivered, small molecule, STAT3 inhibitor.

TTI-101 is completing a first-in-human phase I trial of patients with advanced solid tumors (including hepatocellular carcinoma) who have failed to respond to other lines of therapy. Patients will soon be enrolled in a phase II hepatocellular carcinoma basket trial, which will test TTI-101 as monotherapy and in combination with existing approved therapies across first-, second-, and last-line settings for patients with hepatocellular carcinoma. To date, according to the manufacturer, TTI-101 monotherapy has been well tolerated and has demonstrated clinical activity across a broad range of tumors, including multiple durable radiographic objective responses.

To learn more about the ongoing clinical trial in hepatocellular carcinoma, please visit ClinicalTrials.gov.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.